HomeCompareISSB vs PFE

ISSB vs PFE: Dividend Comparison 2026

ISSB yields 3.99% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $23.6K in total portfolio value· pulled ahead in Year 9
10 years
ISSB
ISSB
● Live price
3.99%
Share price
$18.56
Annual div
$0.74
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.9K
Annual income
$515.18
Full ISSB calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ISSB vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodISSBPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ISSB + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ISSB pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ISSB
Annual income on $10K today (after 15% tax)
$338.98/yr
After 10yr DRIP, annual income (after tax)
$437.90/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,882.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ISSB + PFE for your $10,000?

ISSB: 50%PFE: 50%
100% PFE50/50100% ISSB
Portfolio after 10yr
$37.7K
Annual income
$13,386.95/yr
Blended yield
35.47%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ISSB
No analyst data
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ISSB buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricISSBPFE
Forward yield3.99%6.13%
Annual dividend / share$0.74$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$25.9K$49.6K
Annual income after 10y$515.18$26,258.71
Total dividends collected$4.6K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ISSB vs PFE ($10,000, DRIP)

YearISSB PortfolioISSB Income/yrPFE PortfolioPFE Income/yrGap
1$11,099$398.80$9,153$693.39+$1.9KISSB
2$12,289$413.67$8,593$849.25+$3.7KISSB
3$13,578$428.08$8,336$1,066.78+$5.2KISSB
4$14,970$442.01$8,437$1,384.80+$6.5KISSB
5$16,474$455.46$9,013$1,875.40+$7.5KISSB
6$18,095$468.41$10,306$2,680.72+$7.8KISSB
7$19,843$480.86$12,820$4,101.38+$7.0KISSB
8$21,724$492.80$17,673$6,826.70+$4.1KISSB
9← crossover$23,749$504.24$27,543$12,591.86$3.8KPFE
10$25,927$515.18$49,560$26,258.71$23.6KPFE

ISSB vs PFE: Complete Analysis 2026

ISSBStock

ISSB seeks total return by offering simultaneous leveraged exposure to bitcoin and large-cap US equities, targeting a beta of approximately 1.0 for each. It combines the returns from both beta strategies while seeking to generate income through an options premium strategy overlay. To reach its target beta levels, the fund invests in bitcoin futures, ETFs, ETPs, and options on bitcoin indices, alongside equity futures, ETFs, ETPs, and derivatives. It uses leverage to stack the total return of its bitcoin holdings with the returns of its equity strategy. Essentially, every $1 investment is $1 exposure to bitcoin and $1 to stocks. Futures contracts are rolled over regularly. Collateral investments, including US Treasury bills, money market funds, and cash equivalents, typically comprise 10% to 65% of net assets. The funds realized beta generally ranges between 0.8 and 1.2 for each asset class due to fluctuations. It may also invest up to 25% in a wholly owned Cayman Islands subsidiary.

Full ISSB Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ISSB vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ISSB vs SCHDISSB vs JEPIISSB vs OISSB vs KOISSB vs MAINISSB vs JNJISSB vs MRKISSB vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.